Nektar Therapeutics Ownership | Who Owns Nektar Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Nektar Therapeutics Ownership Summary

Nektar Therapeutics is owned by 61.67% institutional investors, 1.30% insiders, and 37.04% retail investors. Blackrock is the largest institutional shareholder, holding 7.78% of NKTR shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.58% of its assets in Nektar Therapeutics shares.

NKTR Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Nektar Therapeutics	61.67%	1.30%	37.04%
Sector	Healthcare Stocks	57.39%	9.93%	32.68%
Industry	Biotech Stocks	68.48%	9.65%	21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	15.16M	7.78%	$18.79M
Blackrock funding, inc. /de	16.09M	7.69%	$14.97M
Vanguard group	12.33M	5.89%	$11.47M
Samlyn capital	9.67M	4.62%	$8.99M
Nantahala capital management	7.81M	3.73%	$7.26M
Acadian asset management	7.20M	3.44%	$6.69M
Eventide asset management	6.65M	3.18%	$6.18M
Primecap management co/ca/	5.54M	2.65%	$5.15M
Woodline partners lp	4.97M	2.38%	$4.63M
Millennium management	4.52M	2.16%	$4.21M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
22nw, lp	2.19M	1.29%	$2.04M
Altium capital management lp	3.00M	0.79%	$2.79M
Cm management	750.00K	0.62%	$697.50K
Exome asset management	618.17K	0.43%	$574.90K
Tcg crossover management	4.00M	0.36%	$3.72M
Nantahala capital management	7.81M	0.31%	$7.26M
Monaco asset management sam	2.03M	0.27%	$1.89M
Ikarian capital	2.03M	0.26%	$1.89M
Almitas capital	920.23K	0.19%	$855.81K
Samlyn capital	9.67M	0.14%	$8.99M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	15.16M	0.00%	9.28M
Nantahala capital management	7.81M	0.31%	3.70M
Woodline partners lp	4.97M	0.03%	3.24M
Altium capital management lp	3.00M	0.79%	2.99M
State street	2.99M	0.00%	2.30M

Top Sellers

Holder	Shares	% Assets	Change
Deep track capital, lp	1.98M	0.07%	-13.95M
Stonepine capital management	-	-	-3.48M
Eventide asset management	6.65M	0.11%	-2.75M
Lynx1 capital management lp	-	-	-2.07M
Assenagon asset management	-	-	-1.69M

New Positions

Holder	Shares	% Assets	Change	Value
22nw, lp	2.19M	1.29%	2.19M	$2.04M
Exome asset management	618.17K	0.43%	618.17K	$574.90K
Squarepoint ops	139.76K	0.00%	139.76K	$129.97K
Harvest investment services	29.24K	0.01%	29.24K	$27.20K
Cibc world markets	16.71K	0.00%	16.71K	$15.54K

Sold Out

Holder	Change
Assetmark	-22.00
Cubist systematic strategies	-40.00
Capital performance advisors llp	-66.00
Princeton global asset management	-100.00
Nelson, van denburg & campbell wealth management group	-200.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2024	137	-2.84%	129,034,595	-8.31%	61	1.36%	64	6.67%	33	-8.33%
Sep 30, 2024	141	3.68%	140,729,035	3.96%	67	1.39%	61	-15.28%	36	5.88%
Jun 30, 2024	136	10.57%	135,373,255	19.87%	69	2.07%	72	94.59%	34	-29.17%
Mar 31, 2024	123	0.82%	112,937,953	-5.21%	57	1.47%	37	-11.90%	48	-
Dec 31, 2023	122	-6.87%	119,146,708	-16.53%	62	1.12%	42	-12.50%	48	11.63%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Eventide Healthcare & Life Sciences I	6.65M	3.58%	-2.75M
Vanguard Total Stock Mkt Idx Inv	5.72M	3.08%	-
Vanguard US Total Market Shares ETF	5.72M	3.08%	-
iShares Russell 2000 ETF	4.89M	2.63%	-42.35K
PRIMECAP Odyssey Aggressive Growth	3.54M	1.92%	-156.31K
Vanguard Institutional Extnd Mkt Idx Tr	2.66M	1.43%	-
Fidelity Small Cap Index	1.79M	0.96%	-33.51K
iShares Russell 2000 Value ETF	1.70M	0.91%	-
Vanguard Strategic Equity Inv	1.52M	0.82%	-
PRIMECAP Odyssey Growth	1.44M	0.78%	-165.00K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 19, 2025	Zalevsky Jonathan	Chief R&D Officer	Sell	$10.40K
Feb 19, 2025	Wilson Mark Andrew	Chief Legal Officer	Sell	$11.15K
Feb 19, 2025	ROBIN HOWARD W	President & CEO	Sell	$24.01K
Dec 24, 2024	Wilson Mark Andrew	Chief Legal Officer	Sell	$14.74K
Dec 23, 2024	Wilson Mark Andrew	Chief Legal Officer	Sell	$30.06K

Insider Transactions Trends

Date	Buy	Sell
2025 Q1	-	3
2024 Q4	-	8
2024 Q3	-	3
2024 Q2	-	5
2024 Q1	-	3

NKTR Ownership FAQ

Who Owns Nektar Therapeutics?

Nektar Therapeutics shareholders are primarily institutional investors at 61.67%, followed by 1.30% insiders and 37.03% retail investors. The average institutional ownership in Nektar Therapeutics's industry, Biotech Stocks , is 68.48%, which Nektar Therapeutics falls below.

Who owns the most shares of Nektar Therapeutics?

Nektar Therapeutics’s largest shareholders are Blackrock (15.16M shares, 7.78%), Blackrock funding, inc. /de (16.09M shares, 7.69%), and Vanguard group (12.33M shares, 5.89%). Together, they hold 21.36% of Nektar Therapeutics’s total shares outstanding.

Does Blackrock own Nektar Therapeutics?

Yes, BlackRock owns 7.78% of Nektar Therapeutics, totaling 15.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 18.79M$. In the last quarter, BlackRock increased its holdings by 9.28M shares, a 157.82% change.

Who is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested?

22nw, lp is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.29% of its assets in 2.19M Nektar Therapeutics shares, valued at 2.04M$.

Who is the top mutual fund holder of Nektar Therapeutics shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Nektar Therapeutics shares, with 3.58% of its total shares outstanding invested in 6.65M Nektar Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools